Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.
The National Institute for Health and Care Excellence has issued its final draft guidance for Kadcyla, which declares the drug is too expensive to cover.
Researchers have developed a computational cancer model to predict how a drug will perform in humans, VentureBeat reports.
Now that the Pfizer takeover AstraZeneca fought to avoid is on the rocks--at least for the time being--the pressure's on the British drugmaker to deliver strong growth on its own. And while much of the attention is focused on its pipeline, leading cancer drug Zoladex may be able to chip in, too, with new data suggesting it could help prevent infertility in some breast cancer patients receiving chemo.
Glaxo announced at ASCO on Sunday that in a Phase III study, Tykerb and Herceptin failed to improve disease-free survival in HER2-positive early breast cancer patients over Herceptin on its own.
It will allow doctors to spot patients who will benefit from those treatments.
The growing pool of genomics data and bioinformatics capabilities present new opportunities to improve outcomes for cancer patients. Yet without coordinated, multidisciplinary collaborations, the industry risks failing to take full advantage, researchers warned this week.
Perjeta is now the first cancer drug approved to treat patients before surgery. Developed by Roche's Genentech unit, and already approved for women with advanced HER2-positive breast cancer, Perjeta can now reach a huge new group of patients at early stages of the disease.
You might call Perjeta a guinea pig. The new breast cancer drug from Roche's Genentech unit could soon become the first approved for cancer patients before they've had surgery. It would also be the first approved under new FDA guidelines for speeding cancer drugs to patients with early-stage disease.
Roche's study looked at Perjeta in combination with Roche's Herceptin and chemotherapy, compared with Herceptin and chemo alone. Patients on Perjeta and Herceptin saw statistically significant improvements in tumor size compared with those in the Herceptin-only arm, the FDA reveiewers noted.